Searched for
PHARMATRAC SALES DATA
India’s anti-obesity drug market sees slower growth after initial surge in generic semaglutide salesIndia's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...- ORS sales melt in March after govt's stricter labelling normsIndia’s oral rehydration solution (ORS) market has declined after regulatory action restricted the labelling of sugary drinks as ORS, affec...
- Mounjaro sales dip amid price war as semaglutide generics gain groundMounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...
- Cancer drug makers seek 50% price hike as platinum surge hits production viabilityLocal drug manufacturers are struggling to produce essential cancer medicines like carboplatin and cisplatin due to a significant surge in ...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Cardiac drugs log highest sales in 2025 as NCD cases surgeHeart medicines led sales in 2025, a trend set to continue. Respiratory and anti-diabetes drugs followed. Cardiac drug sales grew 13%, with...
- Slimmer price tag helps Wegovy sales gain weightNovo Nordisk has slashed Wegovy prices in India by nearly 40 percent. This move has dramatically increased sales volume by 70 percent in No...
- Respiratory drug sales peak in November amid worsening AQIIndia's air quality decline is boosting medicines for breathing problems. The respiratory drug market grew 8% last month, a rise from previ...
- Weight-loss therapy goes pill-to-shot with higher efficacy, convenienceSales of Novo Nordisk’s oral weight-loss drug Rybelsus have plateaued as Indians increasingly shift to injectable GLP-1 drugs like Eli Lill...
- Under the scanner, yet generic cough syrups hit shelvesWorry is spreading regarding the multitude of cough syrup brands circulating in India, with alarming revelations of toxic diethylene glycol...
- Eli Lilly's obesity drug Mounjaro's India sales hit a sweet spot within six months of launchLilly's Mounjaro has rapidly become the second-highest selling drug in India's pharmaceutical market, achieving ₹233 crore in sales within ...
- Weight-loss drug Mounjaro crosses Rs 100 crore sales in 4 monthsThe drug clocked Rs 47-crore sales in July, double its June figure, according to data from prescriptions tracker PharmaTrac. If this month-...
- Mounjaro crosses Rs 50 cr in India in 90 days as Wegovy joins frayMounjaro, Eli Lilly's weight-loss drug, witnessed a massive sales jump in India since March. Sales reached ₹26 crore in June. Wegovy from N...
- Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demandEli Lilly's Mounjaro has seen a positive reception in India, capturing significant sales and market interest since its launch in March. The...
- Weight-loss drug bulks up sales as patients upgrade dosageEli Lilly's weight-loss and diabetes drug, Mounjaro, has rapidly gained popularity in India, achieving Rs 24 crore in sales within three mo...
- Mercury soars, and so do sales of rehydration drinks in IndiaIndia is experiencing a surge in demand for dehydration-preventing drinks due to the intense heatwave. Electral sales have jumped 27% in Ma...
- Global companies account for 60% of Indian vaccine sales by valueIndia's vaccine market is steadily recovering after the impact from Covid-19 and multinationals are back to slowly gaining traction, sugges...
- Government prohibits 328 fixed dose combinationsThe ban is effective immediately and may shave off over Rs 1,500 crore from India’s Rs 1.18 lakh crore pharmaceutical industry
- Biocon shares gains on cancer drug launchA biosimilar is a near copy of an original complex biologic drug.
- Domestic drug market to grow by 13 per cent in 2013: ResearchThe 72,000-crore domestic drug market could grow between 11% and 13% in 2013, according to projections by pharma market research firms.
Load More
